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SUMMARY
The BCL6 proto-oncogene encodes a transcriptional repressor necessary for the development of
germinal centers (GCs) and directly implicated in lymphomagenesis. Post-GC development of B cells
requires BCL6 downregulation, while its constitutive expression caused by chromosomal transloca-
tions leads to diffuse large B cell lymphoma (DLBCL). Herein we identify a signaling pathway that
downregulates BCL6 expression in normal GC B cells and is blocked in a subset of DLBCL due to
alterations in the BCL6 gene. Activation of the CD40 receptor leads to NF-kB-mediated induction
of the IRF4 transcription factor, which, in turn, represses BCL6 expression by binding to its promoter
region. A subset of DLBCL displays chromosomal translocations or mutations that disrupt the IRF4-
responsive region in the BCL6 promoter and block its downregulation by CD40 signaling.INTRODUCTION
The BCL6 proto-oncogene encodes a transcriptional re-
pressor of the POZ/BTB-zinc finger protein family, which
binds to specific DNA sequences and, via recruitment
of corepressor complexes, represses its target genes
(Chang et al., 1996; Dhordain et al., 1997, 1998; Fujita
et al., 2004; Parekh et al., 2007; Seyfert et al., 1996; Wong
and Privalsky, 1998). Within the B cell lineage, BCL6 is ex-
pressed in the germinal centers (GCs) (Cattoretti et al.,
1995), the structures in which B cells undergo somatic hy-
permutation (SHM) and class switch recombination (CSR)
of immunoglobulin (Ig) genes and are then selected based
on the production of antibodies with high affinity for the an-
tigen (Rajewsky, 1996). BCL6 is a key regulator ofGCdevel-
opment, as mice lacking BCL6 cannot form GCs and fail to
mount secondary T cell-dependent responses due to the280 Cancer Cell 12, 280–292, September 2007 ª2007 Elsevierlackofantibodyaffinitymaturation (Dentetal., 1997;Fukuda
et al., 1997; Ye et al., 1997). Within the GC, BCL6 performs
its biological function by modulating the transcription of
genes controllingDNAdamage responses, cell cycle arrest,
apoptosis, cell activation, differentiation, and CSR (Baron
et al., 1995; Harris et al., 1999; Niu et al., 2003; Parekh
et al., 2007; Phan and Dalla-Favera, 2004; Phan et al.,
2005; Ranuncolo et al., 2007; Shaffer et al., 2000).
In about 15%–40% of DLBCL cases and in 5%–10% of
follicular lymphoma (FL) cases (Baron et al., 1993; Ker-
ckaert et al., 1993; Ye et al., 1993, 1995), chromosomal
translocations place the intact coding region of BCL6
under the control of heterologous promoters derived
from partner chromosomes, resulting in the deregulated
expression of BCL6 by amechanism called promoter sub-
stitution (Chen et al., 1998b; Ohno, 2006; Ye et al., 1995).
In addition, the 50 regulatory region ofBCL6 can be alteredSIGNIFICANCE
Chromosomal translocations andmutations of theBCL6 promoter region are associatedwith40%of DLBCL and
10% of follicular lymphoma, the two most frequent types of B cell lymphoma. These aberrations lead to BCL6
deregulation and cause DLBCL in transgenic mice, but the mechanism of deregulation remains obscure. The re-
sults herein identify a signaling pathway in which CD40 receptor signaling, normally induced by the CD40 ligand on
T cells, leads to downregulation of BCL6. This pathway is blocked in a subset of DLBCL in which the BCL6 pro-
moter region is made unresponsive by structural alterations. Thus, these results identify a mechanism for BCL6
deregulation of direct relevance for the understanding of the pathogenesis of DLBCL.Inc.
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Regulation of BCL6 by CD40-NF-kB-IRF4by mutations introduced by the SHM mechanism in
normal GC B cells (Pasqualucci et al., 1998; Shen et al.,
1998); specific mutations found only in DLBCL (13% of
cases) affect two BCL6-binding sites within the 50 region
of the BCL6 gene and disrupt a negative autoregulatory
circuit (Pasqualucci et al., 2003b; Wang et al., 2002).
Recently, the role of BCL6 in the pathogenesis of DLBCL
was confirmed by showing that mice engineered to ex-
press deregulated BCL6 develop lymphomas displaying
features typical of human DLBCL (Cattoretti et al., 2005).
Consistent with its important role in the GC reaction and
in lymphomagenesis, the expression and activity of BCL6
are tightly regulated. B cell receptor (BCR) engagement
induces MAP-kinase-mediated phosphorylation of BCL6,
leading to its degradation by the ubiquitin proteasome
pathway (Niu et al., 1998). The activity of BCL6 is regulated
through p300-mediated acetylation, which inhibits its
transrepressive function (Bereshchenko et al., 2002). In
addition, early observations suggested that engagement
of the CD40 receptor leads to transcriptional downregula-
tion of BCL6 (Allman et al., 1996; Basso et al., 2004; Niu
et al., 2003). This mechanism is potentially important
since, in GC B cells, CD40 signaling occurs as the result
of interaction with the CD40 ligand presented by T cells
and is involved in multiple events in T cell-dependent an-
tibody responses, including B cell survival and prolifera-
tion, GC and memory B cell formation, and CSR (van
Kooten and Banchereau, 2000). CD40 signaling is not
active in most normal GC B cells, while is detectable in a
subset of centrocytes, suggesting that it may represent an
important mechanism for the downregulation of BCL6 and
for post-GC differentiation of B cells (Basso et al., 2004).
Furthermore, the fact that this mechanism acts on BCL6
transcription suggests that it could be disrupted by chro-
mosomal translocations andmutations affecting theBCL6
promoter region, therefore representing an important
pathogenetic mechanism in B cell lymphomagenesis.
To directly address these issues, this study has explored
further the relationship between CD40 signaling and BCL6
downregulation. The results show that CD40 signaling-
induced downregulation of BCL6 occurs through NF-kB
activation and consequent activation of IRF4, a member of
the interferon-regulatory factor family of transcription fac-
tors required for plasma cell differentiation and expressed
inasubsetofcentrocytesand inABC-typeDLBCL (Alizadeh
et al., 2000; Cattoretti et al., 2006; Falini et al., 2000; Iida
et al., 1997; Klein et al., 2006; Matsuyama et al., 1995;
Sciammas et al., 2006; Wright et al., 2003). IRF4, in turn,
can repress BCL6 transcription by binding to its promoter
region. This pathway is disrupted by translocations andmu-
tations in a subset of DLBCL and Burkitt’s lymphoma (BL),
thus preventing CD40-mediated downregulation of BCL6.
RESULTS
CD40-Induced BCL6 Downregulation Is Mediated
by NF-kB Activation
Since CD40 signaling is transmitted to the nucleus princi-
pally through the activation of NF-kB transcription factorsCanc(Berberich et al., 1994), we investigated whether NF-kB
activation was involved in BCL6 downregulation. In the
Ramos (IkB-ER) cell line, which was engineered to ex-
press a mutant IkB-a protein fused to the estrogen recep-
tor (ER) (Lee et al., 1999), NF-kB is inactivated via two
mechanisms: (1) the mutant IkB-a cannot be phosphory-
lated and targeted for proteosomal degradation, thus pre-
venting the nuclear translocation of NF-kB factors; (2) in
the presence of estrogen, IkB-a-ER proteins can actively
enter the nucleus, displace NF-kB from its binding sites,
and transport it back to the cytoplasm, leading to an addi-
tional level of NF-kB inactivation. As expected, induction
of CD40 signaling by coculture with fibroblasts expressing
the murine CD40 ligand (Basso et al., 2004; Spriggs et al.,
1992) (or with control fibroblasts) in the presence of estro-
gen leads to upregulation of BFL-1 mRNA and protein,
a known CD40 signaling target (Lee et al., 1999), and to
BCL6 downregulation in control Ramos cells (WT). How-
ever, this effect was lost in Ramos (IkB-ER) cells in which
NF-kB is inactivated, indicating that NF-kB activation is
required for BCL6 downregulation by CD40 signaling (Fig-
ures 1A–1C). This result was confirmed in CD40-stimu-
lated P3HRI cells in which NF-kB was pharmacologically
inhibited by a specific NF-kB inhibitor (BAY11-7082) (Fig-
ure 1D). To explore the physiological significance of these
findings, we examined whether the activation of NF-kB
(identified by the nuclear translocation of its p50 and
c-Rel subunits) was associated with downregulation
of BCL6 in normal GC centrocytes by double immunoflu-
orescence analysis of BCL6 expression and p50 or c-Rel
subcellular localization. The results show that the small
subset of centrocytes expressing nuclear p50 (Figure 1E)
or c-Rel (Figure S1 in the Supplemental Data available with
this article online) corresponds precisely to the few centro-
cytes lacking BCL6 expression, consistent with NF-kB ac-
tivation causing BCL6 downregulation. Together, these
results indicate that CD40-mediated downregulation of
BCL6 requires NF-kB activation.
NF-kB Induces IRF4 Transcription
Although required for BCL6 downregulation, NF-kB acti-
vation appeared unlikely to act directly onBCL6 transcrip-
tion, since NF-kB complexes have been reported to act
mainly as transcriptional activators (Pahl, 1999). Among
possible intermediate molecules, IRF4 appeared as
a strong candidate since: (1) its expression is mutually ex-
clusive with BCL6 in GC B cells (Falini et al., 2000); (2) it
can function as a transcriptional repressor on particular
target genes (O’Reilly et al., 2003; Rosenbauer et al.,
1999); and (3) it can be induced byNF-kBat least in human
T cell leukemia virus-I (HTLV1)-transformed T cells
(Sharma et al., 2002). Furthermore, CD40 stimulation in-
duced upregulation of IRF4 and downregulation of BCL6
in transformed GC B cell lines, Ramos, P3HR1, Raji, Mu-
tuI, Ly1, Ly7, and SUDHL4 (Basso et al., 2004)
(Figure S2A and data not shown). Finally, nuclear translo-
cation of NF-kB was found associated with upregulation
of IRF4 in normal GCB cells by immunofluorescence anal-
ysis (data not shown).er Cell 12, 280–292, September 2007 ª2007 Elsevier Inc. 281
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Regulation of BCL6 by CD40-NF-kB-IRF4Figure 1. CD40-Induced BCL6 Down-
regulation Is Mediated by NF-kB
(A) Northern blot analysis for BCL6 expression
in Ramos (WT) and Ramos (IkB-ER) cells upon
CD40 stimulation by coculture with control
fibroblasts (NIH 3T3 ev) or fibroblasts express-
ing CD40L (NIH 3T3 mCD40L) in the presence
of estrogen for 24 hr. The expression of the
NF-kB target BFL-1 was used as positive con-
trol for NF-kB activation by CD40 signaling.
The lymphoblastoid cell line CB33 was used
as a negative and positive control for BCL6
and BFL-1 expression, respectively. GAPDH
expression was used as loading control.
(B) Western blot analysis for BCL6 in Ramos
(WT) and Ramos (IkB-ER) cells upon CD40
stimulation. Protein extracts were obtained
from the same cells used for northern blot anal-
ysis (A). b-Actin was used as a loading control.
(C) Immunofluorescence staining of unstimu-
lated and CD40-stimulated Ramos (WT) and
Ramos (IkB-ER) cells with anti-c-Rel (green)
and anti-BCL6 (red) antibodies. DAPI (blue)
was used for the detection of nuclei.
(D) Western blot analysis for BCL6 in BAY11-
7082-treated P3HR1 cells upon CD40 stimula-
tion. P3HR1 cells were coculturedwith NIH 3T3
ev or NIH 3T3 mCD40L cells for 12 hr with or
without BAY11-7082. b-Actin was used as
loading control.
(E) Immunofluorescence staining of GC B cells.
A human tonsil section was stained with anti-
p50 (red) and anti-BCL6 (green) antibodies.
DAPI (blue) was used for the detection of nu-
clei. Enlargements of selected areas from the
dark zone (DZ) and light zone (LZ) are displayed
on the right (left panel scale bar, 100 mm; right
panel scale bar, 30 mm). White arrows mark
nuclear p50-positive and BCL6-negative cells.Based on these observations, we examinedwhether the
IRF4 locus contained candidate NF-kB-binding sites and
whether direct binding of NF-kB to these sites was detect-
able in vivo by chromatin immunoprecipitation (ChIP) anal-
ysis in unstimulated or CD40-stimulated P3HR1 cells. Of
three potential NF-kB-binding sites on the IRF4 promoter
(‘‘A,’’ ‘‘B,’’ and ‘‘C’’ in Figure 2A), regions A (1232/1032)
and B (605/346) were immunoprecipitated in CD40-
stimulated P3HR1 cells by NF-kB p50 and p65 antibodies,
but not by c-Rel (see below), RelB, p52, and species- and
isotype-matched (control) antibodies. Despite containing
a potential NF-kB-binding site, region C could not be im-
munoprecipitated by any of the antibodies tested
(Figure 2A). The binding of NF-kB was not detected in un-
stimulated P3HR1 cells or in the control region D (+6237/
+6564), which does not contain NF-kB-binding sites. The
lack of binding to the IRF4 promoter for some NF-kB sub-
units was not due to inefficient ChIP analysis, since all five
NF-kB subunits bound to the IkB-a promoter, a known
CD40/NF-kB target (Basso et al., 2004; Ito et al., 1994;
Verma et al., 1995) (Figure 2A, bottom panel). The binding
of p50- and p65-containing complexes to the IRF4
promoter was confirmed by electrophoresis mobility shift282 Cancer Cell 12, 280–292, September 2007 ª2007 Elsevierassays (Figure S2B). Together, these results indicate that
NF-kB can bind to the IRF4 promoter region in vivo. The
selective binding of the p65 and p50 subunits suggests
the involvement of the ‘‘canonical’’ NF-kB pathway (Xiao
et al., 2006).
To confirm that NF-kB is involved in the activation of
IRF4 upon CD40 stimulation in B cells, we used small in-
terference RNA to suppress the expression of p50, p65,
and c-Rel. Western blot analysis showed that the protein
levels of p50, p65, and c-Rel were significantly reduced
in P3HR1 cells after transduction with lentiviruses ex-
pressing siRNAs specific for the three NF-kB subunits
(Figure S2C). When p50 and p65 siRNA-expressing
P3HR1 cells were stimulatedwith CD40L, IRF4 protein up-
regulation was significantly blocked as compared to
P3HR1 cells expressing control siRNAs (Figure 2B). IRF4
upregulation was also blocked in the absence of c-Rel,
despite the lack of direct binding in the ChIP assay, sug-
gesting that c-Rel-containing NF-kB complexes act on
IRF4 transcription indirectly, most likely via induction of in-
termediate molecules or, alternatively, by direct binding to
sequences not presently identified within the IRF4 pro-
moter region. Taken together, these data suggest that,Inc.
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Regulation of BCL6 by CD40-NF-kB-IRF4Figure 2. NF-kB Activates IRF4 Expres-
sion via Binding to Its Promoter Region
upon CD40 Stimulation
(A) Schematic representation of the IRF4 locus.
The DNA fragments (A, B, C, and D) amplified
by PCR following ChIP assays are approxi-
mately positioned below the map. P3HR1 cells
were cocultured with NIH 3T3 ev or NIH 3T3
mCD40L cells for 24 hr. Chromatin was immu-
noprecipitatedwith antibodies recognizing NF-
kB subunits or an irrelevant antibody (rabbit
IgG) as control. Test regions (A, B, and C) and
negative control region (D) were amplified by
PCR. Total chromatin before immunoprecipita-
tion (total input) was used as positive control
for PCR. Samples processed with no antibody
(no Ab) and no DNA (dH2O) were used as
negative controls for ChIP assay and for PCR,
respectively. The PCR amplification of the
IkB-a promoter region (373/62) was used
as positive control for the ChIP assay (bottom
panel). Representative results from one of
three independent experiments are shown.
(B) P3HR1 cells were infected with lentivirus
expressing siRNA specific to p50, p65, or c-Rel
and subjected to puromycine selection. After
coculture with NIH 3T3 ev or NIH 3T3
mCD40L cells for 24 hr, P3HR1 p50 siRNA,
p65 siRNA, c-Rel siRNA, and control siRNA
clones were collected and analyzed by west-
ern blotting using anti-IRF4 and anti-b-Actin
antibodies. Representative results from one
of three independent experiments are shown.upon CD40 stimulation, NF-kB complexes (p50/p65)
activate the expression of IRF4 by direct binding to its
promoter.
IRF4 Suppresses BCL6 Transcription
To investigate whether IRF4 can repress BCL6 transcrip-
tion, we first examined if theBCL6 gene contains potential
IRF4-binding sites. In fact, a total of 25 potential core
IRF4-binding sites (Brass et al., 1999; Escalante et al.,
2002a, 2002b; Furuita et al., 2006; Yoshida et al., 2005)
are detectable within the highly conserved (mouse versus
human) BCL6 50 promoter region (1 kb to +3 kb from
transcription initiation site). Based on this observation,
we examined whether IRF4 binds any of these sites
in vivo using U266 multiple myeloma cells, which express
IRF4 constitutively. ChIP assays for six regions (‘‘A’’–‘‘F’’ in
Figure 3) containing potential IRF4-binding sites within the
50 flanking sequences and the first intron of theBCL6 gene
showed that IRF4 binds specifically to the B (375/80),
C (+400/+696), E (+1452/+1718), and F (+2026/+2268) re-
gions, but not to the A (1562/1244), D (+772/+1031),
and G (+16039/+16301) regions (Figure 3). Identical re-
sults were obtained using three additional DLBCL cell
lines expressing moderate levels of IRF4 upon CD40
stimulation (data not shown; Ly8, RCK8, and VAL; note
that ChIP analysis cannot distinguish between normal
and translocated BCL6 alleles in lines that carry a translo-
cated BCL6 allele; see below). No IRF4 binding was ob-
served in P3HR1 cells, which do not express IRF4 underCancbasal conditions. Thus, regions B, C, E, and F of the
BCL6 promoter represent physiologic targets for IRF4
binding in vivo.
To examine the effect of IRF4 binding on BCL6 gene
transcription, a reporter gene driven by the native BCL6
promoter region, pLA/B9 WT (2913/+4211), was tran-
siently cotransfected into 293T cells with vectors encod-
ing a wild-type IRF4 molecule fused to a myc epitope
tag (myc-IRF4) or a myc-IRF4 mutant (myc-IRF4 DDBD)
lacking the IRF4 DNA-binding domain (Figure 4A and
Figure 7C). The IRF4 expression vector, but not IRF4
DDBD, suppressed the expression of the BCL6 reporter
gene in a dose-dependent manner, indicating that IRF4
represses BCL6 transcription and that DNA binding is re-
quired for this function (Figure 4B).
To determine whether IRF4 can influence the expres-
sion of endogenous BCL6 in native B cells, MutuI cells,
which express BCL6 but not IRF4, were stably transfected
with vectors expressing IRF4-HA or a control vector
(MutuI IRF4-HA and MutuI control; P3HR1 cells could
not be used for this experiment since we could not obtain
stable expression of exogenous IRF4 in these cells). West-
ern blot analysis of clones expressing IRF4 at levels
comparable to those found in most post-GC B cell lines
revealed that the expression of IRF4 leads to a significant
decrease in BCL6 expression (>50%) in MutuI cells
compared to control-transfected cells (Figure 5A). This
result indicates that IRF4 can repress endogenous BCL6
expression in B cells.er Cell 12, 280–292, September 2007 ª2007 Elsevier Inc. 283
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Regulation of BCL6 by CD40-NF-kB-IRF4Figure 3. IRF4 Binds to the BCL6 Pro-
moter Region In Vivo
Schematic representation of the BCL6 locus.
The DNA fragments (A, B, C, D, E, F, and G)
amplified by PCR following ChIP assays are
approximately positioned below the map. The
ChIP assays on U266 and P3HR1 cells were
performed in parallel using equivalent number
of cells. P3HR1 cells that do not express IRF4
were used as negative control for the ChIP as-
say. Chromatin was immunoprecipitated with
anti-IRF4 antibody or an irrelevant antibody
(control IgG) as control. Test regions (A–F)
and negative control region (G) were amplified
by PCR. Samples were processed as de-
scribed in the Figure 2 legend. Representative
results from one of three independent experi-
ments are shown. The right panel (WB) shows
IRF4 and BCL6 protein expression levels in
U266 and P3HR1 cells. a-Tubulin was used
as loading control.To further confirm that BCL6 is a target of IRF4 repres-
sion, we examined the effect of removing IRF4 on BCL6
expression in P3HR1 clones stably transduced with either
IRF4 siRNA or control siRNA. Western and northern blot
analyses showed that, as expected, CD40-mediated up-
regulation of IRF4 is associated with downregulation of
BCL6 in P3HR1 control siRNA clones, whereas no induc-
tion of IRF4 and only a modest downregulation of BCL6
(<20%) were detected in CD40-stimulated P3HR1 IRF4
siRNA clones (Figures 5B and 5C). These results indicate
that IRF4 is required for the transcriptional suppression of
BCL6 in CD40-stimulated B cells.
Validation in Normal GC B Cells
The above-described experiments were performed in
transformed GC B cells (Ramos, P3HR1, and MutuI) be-
cause normal GC B cells cannot be cultured and manipu-
lated in vitro due to rapid mortality (Feuillard et al., 1995;
Liu et al., 1989, 1991). However, the fact that the survival
of these cells can be prolonged by CD40 stimulation al-
lowed us to examinewhether theCD40 signaling pathway,
which induces IRF4 and downregulates BCL6, was oper-
ative in normal cells. As shown in Figure 6A, GC centro-
blasts purified from human tonsils (95% purity) express
BCL6, but not IRF4. CD40 stimulation induces IRF4 and
downregulates BCL6 with a rapid kinetic comparable to
that observed in CD40-stimulated BL lines (Figure S2A;
note that the more rapid downregulation of BCL6 protein
compared to that of IRF4 induction is due to the fact
that a fraction of GC B cells is already undergoing apopto-
sis prior to CD40-induced rescue). To confirm that CD40
signaling acts on BCL6 and IRF4 expression at the
transcriptional level, the transcripts of these genes were
examined in unstimulated and CD40-stimulated normal
GC B cells by qRT-PCR. As shown in Figure 6B, substan-
tial downregulation ofBCL6 and upregulation of IRF4were
detectable in CD40-stimulated cells. To further confirm
that CD40 signaling downregulatesBCL6 and upregulates284 Cancer Cell 12, 280–292, September 2007 ª2007 Elsevier IIRF4 through activation of NF-kB in normal GC B cells, we
examined the subcellular localization of p50 in CD40-
stimulated normal GC B cells by immunofluorescence
analysis. The results show nuclear localization of p50
and IRF4 expression in CD40-stimulated, but not in unsti-
mulated normal GC B cells (Figure 6C). These results, to-
gether with the mutually exclusive expression of IRF4 or
nuclear NF-kB and BCL6 in normal GCs (Figure 1E) (Falini
et al., 2000), support the existence of the CD40-induced,
NF-kB-IRF4-mediated pathway of BCL6 downregulation
in normal GC B cells.
Suppression of BCL6 Is Blocked in Lymphoma
Cells Carrying Chromosomal Translocations
Involving BCL6
Analysis ofBCL6 chromosomal breakpoints indicates that
the majority of them cluster in a region within the BCL6
intron 1 overlapping with the identified major IRF4-binding
domain (Figure 7C), suggesting that these breakpoints
disrupt IRF4-mediated downregulation of BCL6 by CD40
signaling. Thus, we first analyzed the expression of
BCL6 upon CD40 stimulation in DLBCL and BL cell lines
carrying either BCL6 alleles disrupted by translocations
(Ly8, VAL, and RC-K8) or similar ones with nonrearranged
BCL6 loci (Ly1, Ly7, Ramos, P3HR1, MutuI, SUDHL4, and
Raji). With the exception of RC-K8, which constitutively
expresses IRF4 due to a mutation in IkB-a causing consti-
tutive activation of NF-kB (Kalaitzidis et al., 2002), the
CD40-NF-kB-IRF4 pathway appeared to be functional in
all cell lines, as shown by the nuclear translocation of
NF-kB (data not shown) and upregulation of IRF4 (see
Figure 7B for representative data). However, BCL6 down-
regulation was detectable in all seven cell lines carrying
nondisrupted BCL6 alleles (partial downregulation in
Ly1; see below), while all three carrying chromosomal
translocations at the BCL6 locus continued to express
both BCL6 mRNA and protein, as shown by northern
blot (Figure 7A) and western blot analysis (Figure 7B),nc.
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Regulation of BCL6 by CD40-NF-kB-IRF4respectively. Note that the lack of BCL6 downregulation
directly reflects the activity of the translocated BCL6
allele, since the normal allele is silent in all lymphoma
cases with BCL6 translocations (Lossos et al., 2003; Ye
et al., 1995).
The chromosomal breakpoints affect the BCL6 intron 1
region in both the ‘‘CD40-resistant’’ Ly8 and VAL cell lines
(Figure 7C). In VAL cells, the breakpoint separates most of
the IRF4-binding sequences from the coding sequences
of the BCL6 gene and juxtaposes a heterologous TTF pro-
moter region from chromosome 4 (Dallery et al., 1995;
Kerckaert et al., 1993). In Ly8 cells, a similar alteration dis-
rupts region C and eliminates region B, while juxtaposing
the Ig Ig promoter from chromosome 14 (Ye et al., 1995).
In RC-K8 cells, the translocation juxtaposes an unidenti-
fied promoter region from chromosome 14, while leaving
the IRF4-binding regions apparently intact. Notably,
most breakpoints within the BCL6 ‘‘major breakpoint
region’’ (MBR) (Chen et al., 1998a; Pasqualucci et al.,
2003a; Ye et al., 1993) disrupt the BCL6 intron 1 region
in large series of primary DLBCL cases (Akasaka et al.,
2000; Yoshida et al., 1999) (Figure 7C). These observa-
tions indicate that chromosomal translocations can varia-
Figure 4. IRF4 Represses BCL6 Promoter Activity
(A) Schematic representation of wild-type IRF4 (myc-IRF4) and mutant
IRF4 (myc-IRF4DDBD) constructs. IRF4 and IRF4DDBDwere fused to
myc-tag at the N-terminus. The interaction activation domain (IAD) and
DNA-binding domain (DBD) of IRF4 are represented in shaded and
black rectangles, respectively.
(B) The BCL6 promoter-driven luciferase reporter construct, pLA/B9
WT (2913/+4211), was transiently cotransfected into 293T cells
with increasing amounts of myc-IRF4 and myc-IRF4DDBD plasmids.
Data are shown as mean ± SD of three independent experiments.
The lower panel shows the protein expression levels of myc-IRF4
and myc-IRF4 DDBD.Canbly reduce the number of IRF4-binding regions in the
BCL6 promoter in the majority of DLBCL cases, thus
impairing IRF4-mediated BCL6 downregulation.
To examine the contribution of individual portions of
the IRF4-binding domain to IRF4-mediated BCL6 down-
regulation, we constructed luciferase-reporter genes
driven by deletion mutants of the BCL6 promoter region
mimicking the loss of IRF4-binding domains observed in
DLBCL (Figure 7C). We then tested the responsiveness
of these reporters to IRF4-induced suppression in tran-
sient cotransfection assays in 293T cells. The pLA/B9
WT (2913/+4211) reporter, as well as the 30-truncated-
pLA/S5 (2913/+2082) and 50-truncated-pLA/S5 (121/
+2082) reporter constructs displayed comparable repres-
sion (60%–65%) by IRF4, confirming that the IRF4-
responsive domain is largely restricted to the intronic
sequences identified by regions C–F, with a minimal con-
tribution from region B (see slightly reduced suppression
of pLA/S5 [121/+2082]). On the other hand, a significant
reduction in BCL6 reporter downregulation was detect-
able in all constructs containing deletions that variably
affect the C–F domains. In particular, the reporter genes
pLA/S5 (2913/+1777), pLA/S5 (2913/+749), and pLA/
S5 (2913/+203), which lack one (F), two (E and F), or
three (C, E, and F) IRF4-binding regions, were proportion-
ately less suppressible (37%, 7%, and 0%, respectively).
Notably, the last two plasmids, which more closely mimic
the Ly8- and VAL-associated deletions, were virtually un-
responsive to IRF4-induced suppression. These results
indicate that chromosomal translocations frequently dis-
rupt the IRF4-binding region in the BCL6 locus, leading
to the inability of IRF4 to downregulateBCL6 transcription.
Suppression of BCL6 Is Blocked in B Cell
Lymphoma Cells Carrying BCL6 Mutations
The region spanning2 Kb downstream of theBCL6 tran-
scription initiation site and including the 50 portion of intron
1 is targeted by SHM in normal GC B cells and in GC-de-
rived B cell lymphoma, including DLBCL (Migliazza et al.,
1995; Pasqualucci et al., 1998; Shen et al., 1998). Notably,
a subset of DLBCL-associatedmutations (i.e., not found in
normal cells) within the BCL6 exon 1 was shown to disrupt
two BCL6-binding sites and block an autoregulatory cir-
cuit (Pasqualucci et al., 2003b; Wang et al., 2002). Since
numerous mutations can be found also in the IRF4-
responsive domain, we examined whether some of these
mutations could affect BCL6 expression by an alternative
mechanism, i.e., by preventing IRF4-mediated repression.
To this end, we performed transient transfection/reporter
assays using IRF4 expression vectors and a series of re-
porter constructs driven by mutated BCL6 alleles deriving
either from normal GC B cells (n = 7) or B cell lymphoma
cases (five DLBCL and two BL). These alleles were previ-
ously characterized for their mutational status (number of
mutations ranges from 2 to 4 in GCB cells, and 4 to 60 in B
cell lymphoma cases) (Pasqualucci et al., 2003b). Partial
but significant resistance to repression by IRF4 was
observed in two of seven constructs derived from B cell
lymphomas, but in none of seven alleles from normal GCcer Cell 12, 280–292, September 2007 ª2007 Elsevier Inc. 285
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Regulation of BCL6 by CD40-NF-kB-IRF4Figure 5. IRF4 Represses BCL6 Expres-
sion in B Cells
(A) Expression of BCL6, IRF4, HA, and b-Actin
proteins was analyzed by western blot in MutuI
control and MutuI IRF4-HA cells. Unstimulated
and CD40-stimulated P3HR1 and MutuIII cells
were used as positive/negative controls for
expression of IRF4 and BCL6, respectively.
b-Actin was used as loading control.
(B) P3HR1 cells were transducedwith lentivirus
expressing luciferase siRNA (control) or IRF4
siRNA, and single-cell clones were selected.
Western blot analysis for BCL6, IRF4, and
b-Actin was performed on protein extracts of
nine each P3HRI control siRNA and IRF4
siRNA clones after coculture with NIH 3T3 ev
or NIH 3T3 mCD40L cells for 24 hr. The results
obtained from three representative clones (out
of nine tested) are shown. Quantification of
BCL6 protein expression upon CD40 stimula-
tion in P3HR1 control siRNA and IRF4 siRNA
clones is shown on the right. The signal intensi-
ties of BCL6 and b-Actin proteins were mea-
sured by the ImageQuant 5.2 software. b-Ac-
tin-normalized BCL6 expression values are
represented as mean ± SD of nine analyzed
clones.
(C) Northern blot analysis for BCL6 expression
was performed on the same clones shown in
Figure 5B. The signal intensities of BCL6 and
GAPDH mRNA were quantified by the Image-
Quant 5.2 software. BCL6 expression was
normalized using GAPDH, and data are shown
as mean ± SD of three clones (right panel).B cells (Figure 8A). Both the partially resistant Ly1A and
1705B alleles displayed significant dose-dependent resis-
tance when challenged with increasing amounts of IRF4
(Figure 8B). The Ly1A and 1705B alleles carry 60 and 16
mutations, of which 4 and 1 involve core IRF4-binding
sites, respectively. In order to better define the region
that causes the resistance to IRF4-mediated repression
of BCL6 in Ly1A allele, we constructed reporter genes in
which Ly1A and wild-type regions were variably ‘‘swap-
ped’’ (Figure 8C) and tested them for their response to
IRF4 in transient transfection assays. The results show
that the mutations in regions D, E, and F (reporters h, i,
and j in Figure 8C) do not cause resistance to IRF4,
whereas mutations in region C are critical for resistance
(reporters a, e, and g). A minor effect of the BCL6 exon 1
region (compare reporters e versus g) is compatible with
the presence of a mutation in the BCL6 autoregulatory
site (Pasqualucci et al., 2003b; Wang et al., 2002), which
may also be recognized by IRF4 since it contains a core
IRF4-binding motif. Ly1A region C contains 16 mutations,
including two located, respectively, within and in proximity
of a core IRF4-binding site (Figure S3). These mutations
may affect responsiveness to IRF4 individually or in286 Cancer Cell 12, 280–292, September 2007 ª2007 Elsevier Incombination (see Discussion). These results indicate that
a subset of BCL6 alleles found in B cell lymphoma carry
mutations that affect the IRF4-binding region and alter
responsiveness to IRF4.
DISCUSSION
CD40-Induced, NF-kB-Mediated Expression
of IRF4 in GC B Cells
Our results identify a pathway in which CD40 receptor en-
gagement leads to transcriptional activation of the IRF4
transcription factor. IRF4 induction requires activation of
the NF-kB transcription complex, a known mediator of
CD40 signaling (Berberich et al., 1994; Lalmanach-Girard
et al., 1993), since it can be blocked byNF-kB inactivation.
The involvement of NF-kB in IRF4 activation is consistent
with previous observations showing that IRF4 expression
is induced by NF-kB in mitogen-stimulated or virus-
infected T cells (Sharma et al., 2002), and that c-Rel is
involved in the activation of IRF4 by different stimuli in
splenic naive B cells (Grumont and Gerondakis, 2000;
Sharma et al., 2002). Our results demonstrate a direct
role for the p50 and p65 subunits, which bind the IRF4c.
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Regulation of BCL6 by CD40-NF-kB-IRF4promoter region and activate its transcription. In addition,
our results suggest an indirect role for c-Rel in IRF4 induc-
tion in GCB cells, althoughwe cannot exclude direct bind-
ing by c-Rel to sequences of the IRF4 locus more distant
than the ones examined. The involvement of these NF-kB
subunits is consistent with the activity of p50/p65 and
p50/c-Rel NF-kB complexes, and thus indicate that the
‘‘canonical,’’ as opposed to the ‘‘alternative’’ (mediated
by p52/Rel-B), NF-kB pathway (Xiao et al., 2006) is in-
volved in the CD40-mediated activation of IRF4 in GC B
cells. In addition, the observation that IRF4 is located in
the cytoplasm in the Ly7 cell line and can translocate to
the nucleus upon CD40 stimulation (data not shown) sug-
gests the existence of additional mechanisms controlling
IRF4 expression (Mamane et al., 2000).
IRF4-Mediated Downregulation of BCL6
The results herein indicate that the IRF4 transcription
factor binds to the promoter region of the BCL6 gene
Figure 6. CD40 Stimulation Induces NF-kB Activation, IRF4
Upregulation, and BCL6 Downregulation in GC B Cells
(A) Centroblasts purified from human tonsils were cocultured with NIH
3T3mCD40L cells and collected at different time points from 0 to 12 hr.
Western blot analysis was performed using anti-BCL6, anti-IRF4, and
anti-b-Actin antibodies. The Ramos cell line was used as positive con-
trol for BCL6 and IRF4 expression.
(B) qRT-PCR analysis for BCL6 and IRF4 expressions in unstimulated
and CD40-stimulated GC B cells. BCL6 and IRF4 expressions were
normalized using HPRT1, and data are shown as mean ± SD of three
PCR reactions.
(C) Immunofluorescence staining of unstimulated and CD40-stimu-
lated GC B cells with anti-p50 (red) and anti-IRF4 (green) antibodies.
DAPI (blue) was used for the detection of nuclei.Cancand directly represses its transcription. IRF4 is a member
of the interferon regulatory factor (IRF) family of transcrip-
tion factors, whose activity as transactivation or transre-
pression factor is in part determined by cofactors with
which it interacts, as well as by DNA-binding motifs to
which it binds (Marecki and Fenton, 2002). In particular,
IRF4 has been shown to form a heterodimer with IRF8
and synergistically repress the transcription of target
genes by binding to the IFN-stimulated response ele-
ments (ISRE) (Rosenbauer et al., 1999). Although the latter
finding supports the notion that IRF4 can act as a transre-
pressor, IRF8 is unlikely to act as the IRF4 heterodimeric
partner in suppressing BCL6, since IRF8 has been shown
to be coexpressed with and to transcriptionally activate
BCL6 (Lee et al., 2006), and its distribution within the GC
is mutually exclusive with IRF4 (Cattoretti et al., 2006).
Thus, themechanism bywhich IRF4 repressesBCL6 tran-
scription remains to be investigated. The dense distribu-
tion of IRF4-binding sites in the BCL6 promoter region
and the requirement for multiple binding sites for full
BCL6 repression, demonstrated by the analysis of both
DLBCL-associated and experimental mutations (Figures
7 and 8), suggest that oligomerization of IRF4 and possibly
cooperative binding may be required for its function as
a transrepressor (Figure S4).
Previous studies have suggested that CD40 signaling,
as documented by NF-kB activation, occurs only in a sub-
set of centrocytes that are located in the light zone of the
GC (Basso et al., 2004) andmay therefore represent B cells
on their way to post-GC differentiation. The results herein
show that CD40 signaling leads to BCL6 downregulation
in these centrocytes, as demonstrated by experiments in
transformed GC B cells as well as by the validation in nor-
mal lymphoid tissues. Thus, the present results suggest
that T cells/B cells interactions, known to occur within
the light zone of the GC, may be responsible for CD40
ligand-receptor interactions leading toBCL6 suppression.
Other signals functioning through NF-kB may also in-
duce the IRF4-BCL6 pathway. Indeed, transcriptional
downregulation of BCL6, upregulation of IRF4, and nu-
clear translocation of p50were also detected in B cell lines
upon pharmacological induction of DNA damage (data not
shown), which has also been shown to activate the ‘‘ca-
nonical’’ NF-kB pathway (Huang et al., 2003; Wu et al.,
2006). In addition, other members of the TNF receptor
family that, like CD40, function through NF-kB (Xiao
et al., 2006), may induce the same pathway if their ligand
is present in the GC environment. However, BAFF, a cyto-
kine necessary for B cell survival (Schneider et al., 1999),
did not induce downregulation of BCL6 in B cell lines, per-
haps consistent with the fact that its cognate TNF-type
receptor, APRIL (Bossen and Schneider, 2006), functions
mainly via the ‘‘alternative’’ NF-kB pathway (Xiao et al.,
2006), while we show that BCL6 responds to the ‘‘canon-
ical’’ NF-kB signal. Furthermore, BCR signaling, which is
physiologically induced by the antigen in GC B cells and
which has been shown to downregulate BCL6 post-
transcriptionally, can also activate NF-kB, implying its
additional contribution to BCL6 downregulation (Niuer Cell 12, 280–292, September 2007 ª2007 Elsevier Inc. 287
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Regulation of BCL6 by CD40-NF-kB-IRF4Figure 7. CD40-Induced BCL6 Downre-
gulation Is Abrogated in Cell Lines Har-
boring BCL6 Translocation
(A) Northern blot analysis for BCL6 was per-
formed on DLBCL cell lines carrying a translo-
cated (Ly8; VAL; RC-K8) or normal (Ly1) BCL6
locus after coculture with NIH 3T3 ev or NIH
3T3 mCD40L cells for 24 hr. The signal intensi-
ties of BCL6 and GAPDH mRNA were quanti-
fied by the ImageQuant 5.2 software. BCL6 ex-
pression was normalized using GAPDH and
compared between CD40-unstimulated cells
(set as 100%; black bars) and CD40-stimu-
lated cells (gray bars).
(B) Western blot analysis for BCL6 and IRF4
was performed on the same cells used for the
analysis displayed in (A). The signal intensities
of BCL6 and a-Tubulin were measured by the
ImageQuant 5.2 software. BCL6 expression
was normalized using a-Tubulin and compared
between CD40-unstimulated cells (set as
100%; black bars) and CD40-stimulated cells
(gray bars).
(C) Schematic representation of the BCL6ma-
jor breakpoint region (MBR), the BCL6 break-
points in RC-K8, VAL, and Ly8 cell lines (ar-
rows), and the BCL6 reporter constructs. The
DNA fragments analyzed by ChIP assays (see
Figure 3) were positioned below the pLA/B9
WT map. Dashed lines indicate deletions. The
luciferase activities of BCL6 reporter con-
structs were compared between the control
(set as 100%) and myc-IRF4-expressing sam-
ples. All experiments were performed in dupli-
cate, and data are shown as mean ± SD of two
independent experiments.et al., 1998). Overall, these observations suggest that ac-
tivation of NF-kB may represent a common pathway by
which multiple stimuli can induce IRF4 and suppress
BCL6 during the late stages of the GC reaction.
By simultaneously leading to IRF4 induction and BCL6
downregulation, CD40 or other NF-kB-mediated signaling
may contribute to: (1) termination of the GC reaction via
suppression of BCL6, which is required to maintain the
GC phenotype (Dent et al., 1997; Fujita et al., 2004; Ye
et al., 1997); (2) licensing CSR, which requires IRF4 (Klein
et al., 2006; Sciammas et al., 2006); and (3) induction of
plasma cell differentiation, both via upregulation of IRF4,
a required inducer of this process (Klein et al., 2006;
Sciammas et al., 2006), and via suppression of BCL6,
which leads, in turn, to the release of the transcription of
Blimp1, a BCL6 target gene (Tunyaplin et al., 2004; Vasan-
wala et al., 2002) and also a required factor for plasma cell
differentiation (Angelin-Duclos et al., 2000; Shaffer et al.,
2002; Shapiro-Shelef et al., 2003).
Implications for the Pathogenesis of DLBCL
The resistance to IRF4-mediated downregulation may
represent one critical mechanism of BCL6 deregulation288 Cancer Cell 12, 280–292, September 2007 ª2007 Elsevierin tumors carrying BCL6 alleles mutated within the IRF4-
responsive domain. In fact, in these cases, the BCL6
gene is in its normal chromosomal location, and its tran-
scription is driven by its physiologic promoter (Pasqua-
lucci et al., 2003b). Vice versa, most chromosomal trans-
locations juxtapose heterologous promoter regions to the
BCL6 coding domain and, thus, BCL6 expression is regu-
lated by the specific pattern of expression of the various
juxtaposed promoters. Thus, it is conceivable that trans-
locations may affect BCL6 expression by preventing
IRF4-mediated downregulation as well as by juxtaposing
heterologous promoter regions with regulatory properties
different from those of BCL6.
Based on the position of the chromosomal breakpoints
(Figure 7C), complete or partial lack of responsiveness to
CD40-IRF4 may be present in approximately 60% of the
DLBCL carrying chromosomal translocations affecting
BCL6 (30% of all DLBCL), while chromosomal break-
points located outside of the IRF4-responsive region,
such as is the case in the RC-K8 cell line, may affect
BCL6 expression by different mechanisms. Among the
large fraction of DLBCL cases carrying hypermutated
BCL6 alleles (>70%), it is presently unclear whichInc.
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Regulation of BCL6 by CD40-NF-kB-IRF4Figure 8. Somatic Mutations Inhibit
IRF4-Mediated BCL6 Downregulation in
B Cell Lymphomas
(A) Seven BCL6 promoter-driven luciferase
reporter constructs derived from normal GC
lymphocytes and seven reporter constructs
derived from lymphomas (five DLBCL and
two BL) were transiently cotransfected with
control or myc-IRF4 plasmids. Data are shown
as mean ± SD of three independent experi-
ments. p values were calculated using the
Student’s t test.
(B) The luciferase activities of BCL6 reporter
constructs pLA/S5 WT, pLA/S5 Ly1A, and
pLA/S5 1705B were analyzed upon cotrans-
fection with increasing amounts of myc-IRF4.
Data are shown as mean ± SD of three inde-
pendent experiments.
(C) The luciferase activities of pLA/S5WT, pLA/
S5 Ly1A a, and pLA/S5 Ly1Amutants (e, g, h, i,
and j) were analyzed upon coexpression with
myc-IRF4. Data are shown as mean ± SD of
two independent experiments.percentage would display CD40-IRF4 unresponsiveness,
due to the fact that the single allele functional analysis
(Figure 8) is not suitable for the screening of large panels
of cases. Nonetheless, the fact that two of seven non-
Hodgkin’s lymphoma tested displayed an altered re-
sponse suggests that the fraction of involved cases is siz-
able. It should also be noted that the lack of responsive-
ness to CD40-IRF4 may only be relevant to the ABC
subtype of DLBCL, since high levels of IRF4 expression,
as well as evidence of constitutive NF-kB activation, are
preferentially observed in this subtype (6/6 and 4/6 ABC-
DLBCL cell lines, respectively) (Alizadeh et al., 2000; Davis
et al., 2001; Wright et al., 2003) (data not shown).
Based on present knowledge of the biological program
controlled by BCL6, it is conceivable that the lack of BCL6
suppression may contribute to lymphomagenesis by en-
forcing the constitutive suppression of BCL6 target genes
controlling the responses to DNA damage (Phan and
Dalla-Favera, 2004; Ranuncolo et al., 2007), cell cycle ar-
rest (Phan et al., 2005), and plasma cell differentiation (An-
gelin-Duclos et al., 2000; Shaffer et al., 2002; Shapiro-
Shelef et al., 2003). The identification of the intermediate
molecules of CD40-induced BCL6 downregulation willCancallow further testing of the role of this pathway in lympho-
magenesis and, possibly, the design of strategies for its
therapeutic correction.
EXPERIMENTAL PROCEDURES
GC B Cell Purification
GC centroblasts were purified from human tonsils as previously de-
scribed (Klein et al., 2003) and maintained in IMDM supplemented
with 20% FBS. Human tonsils were obtained with approval from the
Columbia University Institutional Review Board as discarded leftovers
from tonsillectomiesperformedat theNewYork-PresbyterianHospital.
qRT-PCR Analysis
Polymerase chain reaction with reverse transcription (RT-PCR) analy-
sis was performed as described previously (Niu et al., 2003). Quantita-
tive real-time RT-PCRwas performedwith SYBRGreen using the 7300
Real Time PCR systems (Applied Biosystems) according to the manu-
facturer’s instructions. The oligonucleotide primers are described in
Table S1.
Transient Transfection and Reporter Assays
293T cells were transiently transfected by using the calcium-phos-
phate precipitation method, and luciferase reporter assays were per-
formed as previously described (Bereshchenko et al., 2002; Changer Cell 12, 280–292, September 2007 ª2007 Elsevier Inc. 289
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Regulation of BCL6 by CD40-NF-kB-IRF4et al., 1996). Each transfection was done in duplicate, and luciferase
activities weremeasured 48 hr posttransfection using a dual-luciferase
reporter assay kit (Promega) according to themanufacturer’s protocol.
ChIP
ChIP assays were performed as described (Niu et al., 2003; Pasqua-
lucci et al., 2003b). The oligonucleotides used for PCR amplification
of immunoprecipitated chromatin fragments are listed in Table S1.
Cell Lines, Plasmids, Lentivirus Vectors,
Immunofluorescence, and Northern and Western Blot
Analysis
These procedures are described in the Supplemental Experimental
Procedures.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, four supplemental figures, and one supplemental table and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/12/3/280/DC1/.
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